About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery

NCT02566525·8 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

CytoSorbents, Inc

Age

18–80

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Elective, cardiac surgery requiring cardiopulmonary bypass with anticipated duration of \>180 minutes

You may not be if

Platelet count \< 20,000/ uL
Body mass index \<18
Pregnant women
Life expectancy of \<14 days
End stage organ disease
Active infection
Undergoing cardiac transplant or ventricular assist device explant, isolated primary coronary artery bypass grafting (CABG) or single valve procedure
Contraindication to anticoagulation with heparin
Declined informed consent

The record

StatusCompleted

PhaseNo phase

Taking part52

StartedNov 2015

UpdatedAug 20, 2021

Conditions

Elective Cardiac Surgery

Where8

University of Kentucky
Lexington, Kentucky, United States
University of Maryland
Baltimore, Maryland, United States
Baystate Medical
Springfield, Massachusetts, United States

Clareo Health | CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery